Cabaletta Bio, Inc. (CABA): Cash & Equivalents
$82.98M
As of 2025-12-31
$225.10M
As of 2026-06-30
+0.6%
3-year compound annual growth
-3.9%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $82.98M | -49.4% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $163.96M | -15.2% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $193.24M | +136.8% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $81.61M | -33.2% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $122.22M | +20.5% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $101.43M | -25.5% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $136.20M | +312.5% | 2021-03-16, Balance as of period end |
| 2018-12-31 | $33.02M | n/a | 2020-03-30, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | 2025-12-31 | $82.98M | -49.4% |
| Aura Biosciences, Inc. (AURA) | 2025-12-31 | $59.52M | +87.8% |
| SAB Biotherapeutics, Inc. (SABS) | 2025-12-31 | $10.50M | +18.0% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $58.13M | -69.5% |
| Compugen Ltd (CGEN) | 2025-12-31 | $90.60M | +397.0% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $12.36M | -24.1% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $110.82M | +29.0% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $94.53M | +680.1% |
| Inhibikase Therapeutics, Inc. (IKT) | 2025-12-31 | $178.80M | +83.4% |
Compare CABA, AURA, SABS, STRO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗